• drapreau en
  • drapreau fr


  • Orateurs Invités

  • Douglas HANAHAN

    Laboratory of Translational Oncology, EPFL, ISREC, Lausanne


    M. Celeste SIMON, Abramson Family Cancer Research Institute, University of Pennsylvania

    M. Celeste Simon, Ph.D. is the Scientific Director of the Abramson Family Cancer Research Institute of the Perelman School of Medicine at the University of Pennsylvania. She received her bachelor's degree from Miami University and completed a Ph.D. in biochemistry at Rockefeller University in 1985. She conducted postdoctoral research with Joseph Nevins at Rockefeller and then Stuart Orkin at Harvard Medical School. Dr. Simon became an Assistant Professor of Medicine/Molecular Genetics and Cell Biology at the University of Chicago in 1992. In its first National Competition, she was named an Assistant Investigator of the Howard Hughes Medical Institute in 1994, remaining an HHMI investigator for twenty years, until August, 2014.

    In 1999, Dr. Simon moved to the University of Pennsylvania School of Medicine and was one of the founding laboratories of the newly formed Abramson Family Cancer Research Institute (AFCRI) there. She was promoted to Associate Professor of Cell and Developmental biology in 1999, and full Professor in 2006. In 2007, she became the Scientific Director of the AFCRI. Dr. Simon's research is focused on how cells sense and respond to changes in the availability of molecular oxygen and nutrients. This affects normal development, physiology, and numerous diseases, such as the growth of solid tumors. The Simon Laboratory is studying how O2 sensing impacts tumor angiogenesis, inflammation, metabolism, metastasis, and overall disease progression. She is studying both animal models and cancer patient samples with the ultimate goal of developing novel strategies to treat tumors such as pancreatic cancer, soft tissue sarcoma, and colorectal cancer. Dr. Simon currently directs a laboratory of 20 individuals, including graduate students, postdoctoral fellows, clinical fellows, and research technicians. The AFCRI employs 400 researchers working in roughly 30 independent laboratories. Dr. Simon has received numerous awards recognizing her research, such as the Fouad Bashour Award for Distinguished Physiologists, Stanley N. Cohen Award for Biomedical Research, and Elliot Osserman Award from the Israel Cancer Research Fund. In 2014, she was elected to the American Academy of Arts and Sciences, as well as the Board of Directors for the American Association for Cancer Research.



    Hervé AVET-LOISEAU

    Cancer Research Center of Toulouse (CRCT)


    Madalena Tarsounas

    Genome stability and tumourigenesis, University of Oxford
     


    Yves Pommier

    Center for Cancer Research, National Cancer Institute, Bethesda

     

    Julie Guillermet, Cancer Research Center of Toulouse (CRCT)
     
    Julie Guillermet-Guibert, team leader of SigDYN is an Inserm Researcher since 2009. The question underlying the following matter, "Which are the distinctive features of cancer cell signalling in physiological conditions and how can we use this knowledge for therapy?", has been the driving force in her career. After obtaining her PhD in 2005, Julie decided to continue her training in UK under the supervision of Prof. Bart Vanhaesebroeck, first in Ludwig Institute of Cancer Research and later in Queen Mary University London (London). During this period, Julie strengthened her knowledge of the biological basis of cell signalling and the utilization of mouse models to mimic a pharmacological intervention. She joined Inserm in 2009 as a permanent researcher with the main objective of studying the unique biological features of cancer cell signalling first in vivo, then modelled ex vivo with an emphasis on the specific pancreatic and ovarian biology. She was awarded an Habilitation by the University Paul Sabatier - Toulouse - in 2015 and then a Jean-Marie Lehn Excellence Prize in 2018 for her work towards a better understanding of resistance to signal-targeted therapies in pancreatic cancer.


    Jean-Christophe Marine

    VIB-KU Leuven Center for Cancer Biology, Leuven
     


    Nikhil C. Munshi

    Dana Farber Cancer Institute, Boston

    Eric Vivier, CIML, Centre d’Immunology de Marseille-Luminy (CIML), Marseille
     
    Éric Vivier, DVM, Ph.D., est professeur d'Immunologie à Aix-Marseille Université et à l'Assistante Publique - Hôpitaux de Marseille.
    Le Pr Vivier a été nommé Directeur Scientifique d'Innate Pharma, société de biotechnologie dédiée à l'amélioration du traitement des cancers grâce à des anticorps thérapeutiques innovants exploitant le système immunitaire.

    Eric Vivier est diplômé de l'Ecole Nationale Vétérinaire de Maisons-Alfort et a reçu son doctorat en Immunologie de l'Université Paris XI. Il a effectué sa formation post-doctorale à Harvard Medical School, puis a rejoint Aix-Marseille Université en tant que professeur au Centre d'Immunologie de Marseille-Luminy (CIML) en 1993 avant d'en devenir le directeur de 2008 à fin décembre 2017.
    Il est également l'un des fondateurs de Marseille-Immunopôle, un cluster d'immunologie créé en 2014 reliant la recherche fondamentale, thérapeutique, l'innovation et le développement industriel dans la région d'Aix-Marseille.

    Les travaux d’Eric Vivier sont focalisés sur le fonctionnement des lymphocytes Natural killer (NK) et des autres cellules innées lymphoïdes (ILCs).

    Le Pr Vivier a publié près de 300 articles scientifiques et fait partie de la liste des chercheurs les plus cités (https://clarivate.com/hcr/ ).
    Lauréat de l’European Research Council (ERC advanced grants), Membre de l’Académie Nationale de Médecine et de l’Institut Universitaire de France, le Pr. Vivier a reçu plusieurs prix dont ceux de la Ligue Nationale contre le Cancer (1996, 2004 et 2013) et de l’European Federation of Immunological Societies (EFIS, 2004).

    Il est également Chevalier de la Légion d'Honneur.


    Jean-Jacques Fournié

    Cancer Research Center of Toulouse (CRCT)


     


    Christian Frezza

    MRC Cancer Unit, University of Cambridge


    Laurent Le Cam

     Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier

    Marina Konopleva, Department of Leukemia, MD Anderson Cancer Center, Houston
     
    I am a Physician-Scientist, Professor, and active member of the clinical faculty in the Departments of Leukemia and Stem Cell Transplantation. My laboratory is studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. I have extended my research to include clinical translational investigations and have developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs. I have also been an active mentor to trainees including undergraduate, medical and graduate students, post-doctoral fellows who have trained under my direction in support of my various laboratory grants and projects.

  • AGENCE PCO PARTENAIRE DE L'ÉVÉNEMENT :
    INSIGHT OUTSIDE
    Comité local d'organisation :
    GIP IUCT
    1 Av. Irène Joliot-Curie
    31100 Toulouse
    * prix depuis ligne fixe opérateur historique, une surtaxe peut être appliquée selon les opérateurs, décompte à la seconde au delà des 45 premières secondes.

    Conformément à la loi Informatique et Libertés, vous disposez d'un droit d'accès et de rectification aux données personnelles vous concernant en vous adressant à INSIGHT OUTSIDE 39 chemin du vieux chêne, 38240 Meylan / France. Conformément à la loi pour la Confiance dans l'Economie numérique du 21 juin 2004, vous pouvez également vous opposer à l'utilisation de vos coordonnées, en envoyant un simple courrier à l'adresse ci-dessus.

    © 2005 - 2019 Insight Outside